Histopathology Reporting and MDT

CPV: Pathology services

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Services

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Unspecified in notice

Recurring procurement

Unspecified in notice

First published

1 Aug 2025, 12:22 BST

Last source update

9 Sept 2025, 11:28 BST

FTS notice number

2025/S 000-054942

Classification (CPV)

Pathology services

Delivery area

South West (UKK23)

Official registry OCID

ocds-h6vhtk-056b3b Find a Tender

Why no open competition

The procurement falls outside the scope of application of the directive

Published justification

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by 13 August 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

Publisher note: This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.<br/><br/>The decision makers were: Deputy Service Group Director - Clinical Support & Cancer Services<br/>No conflicts of interest were declared among decision makers.<br/><br/>The key criteria were weighted as follows:<br/>40% quality and Innovation<br/>15% Value<br/>20% Integration, Collaboration and Service Sustainability<br/>15% Improving access, reducing health inequalities and facilitating choice<br/>10% Social value<br/><br/>Quality is the most important aspect of this service as the level of expertise is extremely hard to find and essential for providing second opinions on complex cancer patients. Integration and collaboration is also essential. <br/><br/>The rationale for choosing the provider with reference to the key criteria:<br/>The existing suppliers are experienced services providers with a proven track record, and they are highly likely to be able to satisfy the new contract to a sufficient standard.

• HAEMATOPATHOLOGY ALLIANCE LTDAwarded supplier 71-75 SHELTON STREET, COVENT GARDEN, LONDON,, London, London, WC2H 9JQ

No document links were published on the notice.